1808 EFFECT OF SACRAL NEUROMODULATION ON FEMALE SEXUAL FUNCTION AND QUALITY OF LIFE

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Peyronie's Disease/Surgical Therapy1 Apr 20111808 EFFECT OF SACRAL NEUROMODULATION ON FEMALE SEXUAL FUNCTION AND QUALITY OF LIFE Mai Banakhar, Yahya Gazwani, Mohamed ElKelini, Tariq Al-shaiji, and Magdy Hassouna Mai BanakharMai Banakhar Toronto, Canada More articles by this author , Yahya GazwaniYahya Gazwani Toronto, Canada More articles by this author , Mohamed ElKeliniMohamed ElKelini Toronto, Canada More articles by this author , Tariq Al-shaijiTariq Al-shaiji Toronto, Canada More articles by this author , and Magdy HassounaMagdy Hassouna Toronto, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2180AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Sacral Neuromodulation (SNM) has become an established option in the treatment of Lower Urinary Tract Symptoms (LUTS). Additional benefits such as improved bowel functions and bladder pain have been reported. Improvement in female sexual functions after SNM treatment has been suggested, however, reports examining the effects of SNM on female sexual functions are scarce. The Purpose of this study is to evaluate the effects of SNM on female sexual function and its impact on the patients' quality of life (QoL). METHODS From January 2010 to October 2010, female patients underwent SNM InterStim® therapy for voiding dysfunction including symptoms of overactive bladder after failed medical and conservative management, Frequency–Urgency Syndrome &Chronic retention . Patients were screened by percutaneous nerve evaluation (PNE) to assess their response to therapy using a 4-day voiding diary. Patients who experienced 50% or more improvement in their voiding parameters were permanently implanted. Female sexual function index (FSFI), short form of health survey (SF-36), and incontinence questionnaires (UDI-6) were completed in all patients preoperatively and 3–5 months postoperatively. RESULTS 19 female patients had SNM InterStim® implanted during that period. 6 patients were excluded from the study because they were not sexually active. The indication (Urge/frequency(6 ), urge incontinence(5) and urinary retention(2)). SNM treatment significantly improved the total FSFI score (p=0.028); the components of arousal and satisfaction showed significant improvement (p=0.037) and (p=0.018) respectively. Age (r=0.278, p=0.357); body mass index (r=−0.037, p=0.905); diagnosis (r=−0.288p=0.339); urinary symptoms (r=0.22, p=0.466) did not show significant correlation with FSFI score improvement. Quality of life showed significant improvement after SNM treatment in five categories. CONCLUSIONS Sacral neuromodulation improves patients' QoL and female sexual function particularly the sexual arousal and satisfaction parameters. Further studies are needed to explain whether the improvement of sexual function is caused by direct sacral neuromodulation or as part of the general improvement in patients' QoL. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e726 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mai Banakhar Toronto, Canada More articles by this author Yahya Gazwani Toronto, Canada More articles by this author Mohamed ElKelini Toronto, Canada More articles by this author Tariq Al-shaiji Toronto, Canada More articles by this author Magdy Hassouna Toronto, Canada More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...